Can UK clinics prescribe compounded peptides?
‘Compounded’ has become a marketing label for cheap unlicensed copies of GLP-1 medicines. UK law does allow prescriber-led supply of unlicensed medicines under the ‘specials’ framework, but the framework is narrow and the marketing version of ‘compounded’ usually doesn't sit inside it.
What ‘compounded’ should mean
Compounding, in the UK pharmaceutical sense, is the preparation of a medicine to a specific prescription for an individual patient where no licensed product is suitable. The relevant route is the “specials” framework under Part 12 of the Human Medicines Regulations 2012. Conditions include:
- A UK prescriber (GMC, GPhC IP, NMC IP, etc.) writes a prescription for an individual patient.
- The prescriber records a special clinical need that no licensed product can meet (allergy to an excipient, unavailable strength, paediatric formulation, etc.).
- The product is manufactured by a holder of a manufacturer’s “specials” licence (MS), or imported under a separate exemption with the appropriate notification.
- The prescriber retains clinical responsibility for the prescription.
A genuine UK ‘special’ is comparatively rare. It is a clinical tool for edge cases.
What ‘compounded’ has come to mean in GLP-1 marketing
A different category of supply has emerged in the consumer GLP-1 market:
- Generic-vial semaglutide or tirzepatide marketed alongside, or instead of, the branded pen.
- Sold to the general public via online clinics on the basis of price (e.g. “half the cost of Wegovy”).
- Frequently sourced from non-UK manufacturers without a UK MS licence.
- Dispensed against a quick-form online assessment rather than a documented clinical justification for choosing an unlicensed preparation over the licensed product.
This is not the “specials” framework. It is consumer supply of an unlicensed medicine using compounding language as cover. The MHRA has been explicit that compounded GLP-1s marketed this way are an enforcement priority and that patients face quality, dosing, and contamination risks.
Why the price gap is a red flag, not a feature
Licensed GLP-1 pens (Wegovy, Mounjaro, Saxenda) have manufacturing, quality-assurance, regulatory, and pharmacovigilance costs baked into the price. A ‘compounded’ alternative offered at a fraction of the price is signalling that some of those costs aren’t being paid — which usually means quality assurance, traceability, or batch testing.
- Concentration variability between vials — documented in independent testing of compounded GLP-1 products elsewhere in the world.
- Substitutions (e.g. semaglutide sodium versus semaglutide free acid) that change pharmacokinetics and dosing assumptions.
- Stability and sterility issues from non-GMP filling.
- No PIL, no reliable adverse-event reporting chain, no recall mechanism if a batch fails.
When a UK clinic supply can be lawful
- The clinic is dispensing a UK-licensed POM (Wegovy, Mounjaro, Saxenda, Ozempic, Rybelsus) from a GPhC-registered pharmacy against a real clinical assessment.
- The clinic is using the genuine ‘specials’ framework for an individual patient with documented clinical need that no licensed product can meet — and can name the MS-licensed manufacturer.
- The prescriber takes documented personal clinical responsibility and is named, GMC-registered, and contactable.
For unlicensed research peptides like BPC-157, TB-500, CJC-1295, MOTS-c, etc., the “specials” argument doesn’t easily reach them. There is no UK-licensed equivalent they would be compounded as a substitute for, and the clinical-need justifications used in genuine specials supply do not translate.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Compounded semaglutide — same active ingredient, half the price”
Mass-market price-led compounded GLP-1 supply is the pattern MHRA has acted against. Price gap usually reflects skipped quality-assurance costs.
“Bespoke compounded BPC-157 — prescribed by our doctor”
BPC-157 has no UK marketing authorisation. The ‘specials’ framework requires a licensed equivalent it's being prescribed as a substitute for. There isn't one.
“UK-compounded — manufactured in our partner facility”
‘Manufactured in our facility’ is not the same as ‘manufactured by an MHRA-licensed MS holder’. Ask for the MS licence number.
“Compounded Mounjaro — no waiting list”
The NHS waiting list isn't a clinical justification for substituting an unlicensed product. It's a market opportunity. The ‘specials’ framework doesn't accommodate it.
Sources & further reading
- MHRA — gov.uk
- MHRA Drug Safety Update — publication landing — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk
- NICE TA875 — semaglutide for weight management — nice.org.uk
- NICE TA1026 — tirzepatide for weight management — nice.org.uk
Frequently asked questions
- Is ‘compounded semaglutide’ legal in the UK?
- Not in the form most online clinics advertise it. Lawful UK ‘specials’ supply of an unlicensed medicine requires a special clinical need that a licensed product cannot meet, a prescriber taking personal clinical responsibility, and manufacture by a holder of a manufacturer's ‘specials’ licence (MS). Mass-market compounded GLP-1s sold on price do not fit this picture.
- What is the UK ‘specials’ framework?
- The Human Medicines Regulations 2012 allow a UK prescriber to prescribe an unlicensed medicinal product in narrow circumstances (often called a ‘special’). The product must be manufactured by an MHRA-licensed ‘specials’ manufacturer or imported under specific exemptions. The exemption exists for genuine clinical need where no licensed product is suitable — for example, an allergy to an excipient in the licensed version, or a paediatric formulation.
- Is BPC-157 a UK ‘special’?
- No. BPC-157 has no UK marketing authorisation and no recognised licensed-medicine equivalent it would be compounded as a substitute for. A UK prescriber attempting to write a BPC-157 prescription on a ‘specials’ basis would struggle to evidence the special clinical need the framework requires.
- What action has the MHRA taken on compounded peptides?
- The MHRA has issued public warnings about counterfeit and ‘compounded’ semaglutide reaching UK patients via online routes and has prosecuted illegal supply. See the MHRA Drug Safety Update landing page for the current position.
- How can I tell a real ‘specials’ supply from a marketing ‘compounded’ supply?
- A real special is dispensed in response to a prescription written for an individual patient with documented clinical need, manufactured by a licensed MS holder named on the dispensing label. A marketing ‘compounded’ supply is advertised to the public on price, made available without an individualised clinical justification, and frequently has no traceable MS-licensed manufacturer.